Christopher Sarchi Sells 12,000 Shares of Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Sarchi also recently made the following trade(s):

• On Thursday, April 2nd, Christopher Sarchi sold 6,500 shares of Replimune Group stock. The shares were sold at an average price of $8.01, for a total value of $52,065.00.

Replimune Group Stock Down 1.1%

Shares of REPL stock opened at $9.87 on Friday. Replimune Group, Inc. has a 1 year low of $1.50 and a 1 year high of $13.24. The stock has a market cap of $815.00 million, a PE ratio of -2.87 and a beta of 0.91. The business’s fifty day moving average is $5.08 and its 200-day moving average is $7.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60.

Institutional Investors Weigh In On Replimune Group

Large investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP acquired a new stake in shares of Replimune Group in the first quarter worth $921,000. Essential Partners LLC raised its position in Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after buying an additional 5,624 shares during the period. Bank of America Corp DE raised its position in Replimune Group by 17.7% during the first quarter. Bank of America Corp DE now owns 253,449 shares of the company’s stock valued at $1,939,000 after buying an additional 38,119 shares during the period. Readystate Asset Management LP purchased a new stake in Replimune Group in the 1st quarter worth about $1,059,000. Finally, EcoR1 Capital LLC purchased a new stake in Replimune Group in the 1st quarter worth about $7,650,000. 92.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on REPL. BMO Capital Markets lowered Replimune Group from a “market perform” rating to an “underperform” rating in a research note on Monday, April 13th. Wedbush raised their price objective on Replimune Group from $2.00 to $6.00 and gave the stock a “neutral” rating in a research note on Monday. HC Wainwright reissued a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. Leerink Partners reissued a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Finally, Cantor Fitzgerald lowered Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Seven research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $4.88.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.